Codexis (CDXS) Issues Quarterly Earnings Results

Codexis (NASDAQ:CDXS) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.03, Morningstar.com reports. The company had revenue of $16.95 million for the quarter, compared to the consensus estimate of $14.63 million. Codexis had a negative return on equity of 61.93% and a negative net margin of 29.83%. Codexis updated its FY 2018 guidance to EPS.

Shares of NASDAQ:CDXS traded down $1.01 during trading on Friday, hitting $15.71. 341,487 shares of the stock were exchanged, compared to its average volume of 301,554. Codexis has a 1-year low of $5.70 and a 1-year high of $19.60. The firm has a market capitalization of $905.96 million, a PE ratio of -31.42 and a beta of -1.60.

In related news, Director Bernard J. Kelley sold 10,207 shares of the business’s stock in a transaction on Friday, September 21st. The stock was sold at an average price of $18.12, for a total value of $184,950.84. Following the sale, the director now owns 215,461 shares of the company’s stock, valued at approximately $3,904,153.32. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John J. Nicols sold 14,259 shares of the business’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $15.14, for a total value of $215,881.26. Following the completion of the sale, the insider now directly owns 1,084,538 shares in the company, valued at approximately $16,419,905.32. The disclosure for this sale can be found here. Insiders have sold a total of 508,329 shares of company stock worth $8,354,797 in the last three months. 11.40% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in CDXS. Millennium Management LLC acquired a new stake in Codexis in the 1st quarter valued at $349,000. Campbell & CO Investment Adviser LLC acquired a new stake in Codexis in the 2nd quarter valued at $146,000. Baillie Gifford & Co. boosted its stake in Codexis by 14.9% in the 2nd quarter. Baillie Gifford & Co. now owns 2,646,240 shares of the biotechnology company’s stock valued at $38,107,000 after buying an additional 343,261 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Codexis in the 2nd quarter valued at $891,000. Finally, Gilder Gagnon Howe & Co. LLC boosted its stake in Codexis by 5.6% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 219,435 shares of the biotechnology company’s stock valued at $3,160,000 after buying an additional 11,562 shares in the last quarter. 77.40% of the stock is currently owned by institutional investors and hedge funds.

CDXS has been the topic of several recent analyst reports. BidaskClub downgraded Codexis from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. Zacks Investment Research raised Codexis from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Thursday, August 16th. Finally, Craig Hallum lifted their price objective on Codexis from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, September 5th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Codexis has an average rating of “Buy” and a consensus price target of $16.40.

COPYRIGHT VIOLATION NOTICE: This story was first published by Stock Observer and is owned by of Stock Observer. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.thestockobserver.com/2018/11/10/codexis-cdxs-issues-quarterly-earnings-results.html.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

See Also: What are Institutional Investors?

Earnings History for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply